<?xml version="1.0" encoding="UTF-8"?>
<p>Moreover, anti-M2e Abs have shown to be protective in humans. In a controlled challenged study, the administration of a specific anti-M2e IgG mAb (TCN-032), showed a reduction of 35% of symptoms compared to group that received placebo, when challenged with influenza virus A/Wisconsin/67/2005 (H3N2) (
 <xref rid="B110" ref-type="bibr">110</xref>). Also, several phase I and II clinical trials of M2e-based vaccines have shown to be safe and immunogenic in humans (
 <xref rid="B103" ref-type="bibr">103</xref>, 
 <xref rid="B111" ref-type="bibr">111</xref>, 
 <xref rid="B112" ref-type="bibr">112</xref>), and recently a phase I clinical trial started to evaluate a hepatitis B core-M2e-based vaccine in Russia (NCT03789539) (
 <xref rid="B113" ref-type="bibr">113</xref>).
</p>
